MA30273B1 - Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires. - Google Patents

Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires.

Info

Publication number
MA30273B1
MA30273B1 MA31228A MA31228A MA30273B1 MA 30273 B1 MA30273 B1 MA 30273B1 MA 31228 A MA31228 A MA 31228A MA 31228 A MA31228 A MA 31228A MA 30273 B1 MA30273 B1 MA 30273B1
Authority
MA
Morocco
Prior art keywords
hydroxy
methoxyphenylcarbamoyl
dihydroquinolin
piperidin
oxo
Prior art date
Application number
MA31228A
Other languages
English (en)
French (fr)
Inventor
Reshma Chudasama
Andrew Kennedy
Leanda Jane Kindon
Franck Patrick Mallet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36119909&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA30273(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30273B1 publication Critical patent/MA30273B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA31228A 2006-02-10 2008-09-10 Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires. MA30273B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0602778.3A GB0602778D0 (en) 2006-02-10 2006-02-10 Novel compound

Publications (1)

Publication Number Publication Date
MA30273B1 true MA30273B1 (fr) 2009-03-02

Family

ID=36119909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31228A MA30273B1 (fr) 2006-02-10 2008-09-10 Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires.

Country Status (33)

Country Link
US (1) US7960551B2 (OSRAM)
EP (1) EP1981872B1 (OSRAM)
JP (1) JP5616021B2 (OSRAM)
KR (1) KR101488691B1 (OSRAM)
CN (1) CN101379057B (OSRAM)
AR (2) AR059409A1 (OSRAM)
AU (1) AU2007213767B2 (OSRAM)
BR (1) BRPI0707559B8 (OSRAM)
CA (1) CA2641769C (OSRAM)
CR (1) CR10227A (OSRAM)
CY (1) CY1119238T1 (OSRAM)
DK (1) DK1981872T3 (OSRAM)
EA (1) EA016580B1 (OSRAM)
ES (1) ES2640226T3 (OSRAM)
GB (1) GB0602778D0 (OSRAM)
HR (1) HRP20171304T1 (OSRAM)
HU (1) HUE034315T2 (OSRAM)
IL (1) IL193103A (OSRAM)
JO (1) JO3389B1 (OSRAM)
LT (1) LT1981872T (OSRAM)
MA (1) MA30273B1 (OSRAM)
MY (1) MY153656A (OSRAM)
NO (1) NO341343B1 (OSRAM)
NZ (1) NZ570242A (OSRAM)
PE (2) PE20110120A1 (OSRAM)
PL (1) PL1981872T3 (OSRAM)
PT (1) PT1981872T (OSRAM)
SG (1) SG169404A1 (OSRAM)
SI (1) SI1981872T1 (OSRAM)
TW (1) TWI401251B (OSRAM)
UA (1) UA100364C2 (OSRAM)
WO (1) WO2007090859A1 (OSRAM)
ZA (1) ZA200806782B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519138B2 (en) * 2009-04-14 2013-08-27 Glaxo Group Limited Process for the preparation of a biphenyl-2-yl carbamic acid ester
AU2015234331B2 (en) * 2009-04-23 2017-08-03 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN102405218B (zh) 2009-04-23 2014-06-04 施万制药 具蕈毒碱受体拮抗剂和β2 肾上腺素受体激动剂活性的二酰胺化合物
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) * 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
WO2013017494A1 (en) * 2011-08-02 2013-02-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical composition of oxidised avidin suitable for inhalation
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
JP6307091B2 (ja) 2012-12-18 2018-04-04 アルミラル・ソシエダッド・アノニマＡｌｍｉｒａｌｌ， Ｓ．Ａ． β２アドレナリンアゴニスト活性およびＭ３ムスカリンアンタゴニスト活性を有する新規のシクロヘキシルおよびキヌクリジニルカルバメート誘導体
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
GB201500447D0 (en) * 2015-01-12 2015-02-25 Glaxosmithkline Ip Dev Ltd Novel Combination Product
CN106632257B (zh) * 2016-12-15 2019-02-12 上海市奉贤区中心医院 Gsk961081及其中间体的合成方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022776A (en) * 1974-01-31 1977-05-10 Otsuka Pharmaceutical Company Limited 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives
DE3134590A1 (de) 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US4894219A (en) * 1988-03-29 1990-01-16 University Of Florida Beta-agonist carbostyril derivatives, assay method and pharmacological composition
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
DK0640081T3 (da) 1992-03-31 2000-06-19 Glaxo Group Ltd Substituerede phenylcarbarmater og phenylurinstoffer, deres fremstilling og deres anvendelse som 5-HT4-antagonister
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
EP0863141B1 (en) 1995-10-13 2001-09-12 Banyu Pharmaceutical Co., Ltd. Substituted heteroaromatic derivatives
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999031086A1 (en) 1997-12-12 1999-06-24 Smithkline Beecham Plc Quinolinepiperazine and quinolinepiperidine derivatives, their preparation and their use as combined 5-ht1a, 5-ht1b and 5-ht1d receptor antagonists
JP2002517464A (ja) 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド ムスカリン性レセプターアンタゴニスト
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6713651B1 (en) * 1999-06-07 2004-03-30 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6593497B1 (en) * 1999-06-02 2003-07-15 Theravance, Inc. β2-adrenergic receptor agonists
AU783095B2 (en) 1999-12-07 2005-09-22 Theravance Biopharma R&D Ip, Llc Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) * 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
JP4445704B2 (ja) 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびｍ３アンダゴニストとしてのそれらの使用
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
US6653323B2 (en) * 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
TWI249515B (en) * 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
ES2248767T3 (es) 2002-04-12 2006-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Medicamento que contiene beta-mimeticos y un nuevo anticolinergico.
JP2005527618A (ja) * 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US7317102B2 (en) 2003-04-01 2008-01-08 Theravance, Inc. Diarylmethyl and related compounds
EP1626970B1 (en) * 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
US7320990B2 (en) * 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
JP2008510015A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物

Also Published As

Publication number Publication date
PL1981872T3 (pl) 2017-11-30
CY1119238T1 (el) 2018-02-14
CR10227A (es) 2008-10-29
NO20083425L (no) 2008-09-09
CN101379057A (zh) 2009-03-04
EP1981872A1 (en) 2008-10-22
BRPI0707559A2 (pt) 2011-05-10
JP5616021B2 (ja) 2014-10-29
AR104288A2 (es) 2017-07-12
PE20071249A1 (es) 2008-01-16
UA100364C2 (xx) 2012-12-25
EA016580B1 (ru) 2012-06-29
ZA200806782B (en) 2009-10-28
BRPI0707559B8 (pt) 2021-05-25
WO2007090859A1 (en) 2007-08-16
KR20080114723A (ko) 2008-12-31
KR101488691B1 (ko) 2015-02-02
PT1981872T (pt) 2017-09-13
DK1981872T3 (en) 2017-09-11
TW200800948A (en) 2008-01-01
ES2640226T3 (es) 2017-11-02
IL193103A0 (en) 2009-02-11
AR059409A1 (es) 2008-04-09
NZ570242A (en) 2011-09-30
TWI401251B (zh) 2013-07-11
BRPI0707559A8 (pt) 2019-01-29
CN101379057B (zh) 2013-02-13
PE20110120A1 (es) 2011-03-08
US7960551B2 (en) 2011-06-14
BRPI0707559B1 (pt) 2021-01-12
AU2007213767A1 (en) 2007-08-16
SI1981872T1 (sl) 2017-10-30
CA2641769C (en) 2014-02-04
JO3389B1 (ar) 2019-03-13
US20070281971A1 (en) 2007-12-06
LT1981872T (lt) 2017-09-11
SG169404A1 (en) 2011-03-30
AU2007213767B2 (en) 2012-04-26
IL193103A (en) 2013-06-27
MY153656A (en) 2015-03-13
NO341343B1 (no) 2017-10-16
HUE034315T2 (en) 2018-02-28
CA2641769A1 (en) 2007-08-16
JP2009526018A (ja) 2009-07-16
EP1981872B1 (en) 2017-06-21
EA200801691A1 (ru) 2009-02-27
HRP20171304T1 (hr) 2017-10-20
GB0602778D0 (en) 2006-03-22

Similar Documents

Publication Publication Date Title
MA30273B1 (fr) Sel d'acide succinique de l'ester 1-{2-(2-chloro-4-{[(r)-2-hydroxy-2-oxo-1,2- dihydroquinolin-5-yl)methoxyphenylcarbamoyl)ethyl]piperidin-5-ylique de l'acide biphenyl-2-ylcarbamique et son utilisation pour le traitement de troubles pulmonaires.
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
TW200613296A (en) Crystalline form of a biphenyl compound
EP1993365A4 (en) BIOLOGICALLY AVAILABLE CURCUMINOID FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER DISEASES RELATED TO THE AGE
EP2268647A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP2149047A4 (en) POLYMORPHISMS IN GENES WITH INFLUENCE ON DOPAMINTRANSPORTER DISEASES AND ITS APPLICATIONS
EP2567701A3 (fr) Traitement de l'insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l'aldostérone.
MA28084A1 (fr) Formes polymorphes de 3-(4-amino-1-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
MA38071B1 (fr) Formes cristallines d'un inhibiteur de facteur xia
EP2061314A4 (en) CONNECTIONS TO IMPROVE LEARNING AND MEMORY
EP1771201A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OXALATE-RELATED DISEASE
DE60212146D1 (de) Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
MA29451B1 (fr) Association entre la ferroquine et un derive d'artemisinine pour le traitement du paludisme
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MXPA04003298A (es) Compuestos de piperidina como antagonistas muscarinicos.
EP2004164A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF DEGENERATIVE AND INFLAMMATORY DISEASES
EP1496721A3 (en) Flat display apparatus
FR2911609B1 (fr) Copolymere dibloc comprenant des unites derivant du styrene et des unites derivant d'acide acrylique
FI20060247L (fi) Bakteeri-itiöiden muodostumisen estäminen kartonkikoneen hylkysysteemissä
MA27730A1 (fr) Combinaisons de paroxetine et de 4-(s)-(4-acetyl-piperazin-1-yl-)-2-(r)-(4-fluoro-2-methyl-phenyl)-piperidine-1-acide carboxylique[1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide utilisees dans le traitement de la depression et/ou de l'anxiete
FR2900049B1 (fr) Utilisation d'un derive de 4-amino piperidine comme agent pour induire et/ou stimuler la pousse des fibres keratiniques et /ou freiner leur chute
EP1745000A4 (en) NEW ANTHRACHINONE, MANUFACTURING METHOD AND USE THEREOF
EP2332932A4 (en) NEW CRYSTALLINE FORMS OF 4- (2-AMINOPYRIDIN-4-YL) -3- (4-fluoro-PHENYL) -1- (1,4,5,6-TETRAHYDRO-6-OXOPYRIDAZIN-3-YL) -1H-PYRAZOLE -METHANESULPHONATE AND METHOD OF MANUFACTURING THEREOF
FR2840618B1 (fr) Procede pour ameliorer les proprietes physico-chimiques de compositions de bitume ainsi que de nouvelles compositions de bitume aux proprietes ameliorees et leurs utilisations